Cloning of rat 92-kDa type IV collagenase and expression of an active recombinant catalytic domain  by Xia, Yiyang et al.
FEBS 16799 FEBS Letters 382 (1996) 285-288 
Cloning of rat 92-kDa type IV collagenase and expression of an active 
recombinant catalytic domain 
Yiyang Xia, Gabriela Garcia, Shizhong Chen, Curtis B. Wilson, Lili Feng* 
Department of Immunology, The Scripps Research Institute, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA 
Received 1 February 1996 
Abstract A full-length cDNA for rat 92-kDa type IV 
collagenase was isolated and sequenced. RNase protection assay 
revealed tissue specific differential expression of the 92-kDa type 
IV collagenase in the rat during development. Natural and 
modified forms of the 92-kDa type IV collagenase were 
expressed. One active protein, 92-CD, contained only the 
putative catalytic domain. Large quantities of the 92-CD were 
expressed in Escherichia coli, extracted from inclusion bodies, 
purified, and refolded to an active form. This recombinant 
protein was able to cleave denatured and native collagen and was 
inactivated by known MMP inhibitors. 
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1. Introduction 
The extracellular matrix (ECM) provides tructural support 
and assists in cell proliferation, adhesion, migration, and tis- 
sue morphogenesis. The mammalian matrix metalloprotei- 
nases (MMPs) degrade ECM in physiological nd pathologi- 
cal processes involving extensive ECM remodeling (reviewed 
in [1]). The MMPs are structurally homologous and evolutio- 
narily related molecules composed of defined functional do- 
mains [2,3]. After cleavage of a signal peptide domain of 
about 20 amino acids, the MMPs are secreted in latent 
form. Upon activation, the N-terminal propeptide domain is 
cleaved to leave the active form of the MMP [4]. With the 
exception of matrilysin, the active MMPs have a common 
domain structure consisting of a catalytic domain, a linker 
peptide, and a C-terminal domain with sequence similarity 
to hemopexin and to the ECM component vitronectin; ma- 
trilysin lacks the C-terminal domain. The C-terminal domain 
is essential for complexing the proenzyme with tissue inhibitor 
of metalloproteinase (TIMP) [5]. The activity of the MMPs 
can be inhibited by endogenous inhibitors like ct-2 macroglo- 
bulin and tissue inhibitors of metalloproteinases as well as by 
rapid autodegradation f the C-terminal domain. 
Like other members of the MMP family, the 72-kDa and 
92-kDa type IV collagenases [gelatinase A (MMP-2); gelati- 
nase B (MMP-9)] contain the basic structure of propeptide, 
catalytic, and hemopexin domains [6-8]. They differ from 
other MMPs by the presence of three 58-59-amino acid resi- 
due internal repeats that are homologous to the collagen- 
binding domains of fibronectin, and the 92-kDa type IV col- 
lagenase has an additional domain that is similar to type V 
collagen [6,9]. They are located on a different chromosome 
than other members of the MMP family [3]. The type IV 
collagenases are of special interest because of their degrada- 
tive activity against basement membrane type IV collagen and 
their expression in cells of emigrational or invasive nature 
during physiological nd pathological processes [10-14]. The 
mechanisms by which type IV collagenases contribute to phy- 
siological and pathological processes remain incompletely un- 
derstood. The aim of the present study was to clone the rat 
92-kDa type IV collagenase cDNA, express and purify an 
active and stable modified recombinant protein in /~: coli, to 
allow better characterization f its in vitro and in vivo proper- 
ties. The removal of the propeptide obviated the need for 
proteolytic or organomercurial activation, and the removal 
of the C-terminal fragment eliminated autolytic sites and 
made the recombinant protein resistant o autodegradation 
ideal for experimental usage. 
2. Materials and methods 
2.1. Cloning rat 92-kDa type IV collagenase 
A 262 bp probe (bp 371433 of the mouse clone) was cloned by 
RT-PCR with primers elected from conserved regions between mouse 
and human (Genbank accession nos. : x72795 and J05070) and used to 
screen a rat macrophage cDNA library [15]. Isolated phage plaques 
were subjected to in vivo excision for recombinant pBluescript pha- 
gemid. After sequencing, it was found that the cloned cDNA lacked 
375 bp at the 5' end of the mRNA of rat 92-kDa type IV collagenase 
(clone pM92-1.9). To obtain the 5' end cDNA, RT-PCR was per- 
formed with a degenerate upstream primer based on homologies 
with the 5' end of the human and mouse sequence, 5'-GCTCTA- 
GAATGAG(TC)CCCTGGCAGCCCCTG-3', and the downstream 
primer, 5'-CTCAAGTGGCACCATCATAACATC-3', according to 
the 5' end sequence ofpRat92-3. RNA was isolated from fetal kidney 
and was reverse transcribed. 
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2.2. Tissue-specific expression of 72-kDa and 92-kDa type IV collage° 
nase 
5 I-tg of total RNA from fetal and adult rat organs was studied by 
RNase protection assay [16]. For the rat 92-kDa type IV collagenase, 
a 375 nucleotide riboprobe was transcribed from the PCR-cloned 
cDNA (Fig. 1). For the rat 72-kDa type IV collagenase, a cDNA 
clone was obtained from Dr. David Lovett (Veterans Affairs Medical 
Center, San Francisco, CA) to generate a 222 nucleotide riboprobe. A
third probe, the 114 nucleotide riboprobe of the glyceraldehyde-3- 
phosphate dehydrogenase (GAP), was used to normalize the amounts 
of RNA in different lanes. 
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2.3. Expression and characterization of rat 92-kDa type IV collagenase 
and its catalytic domain (92-CD) 
For the expression of 92-CD, a fragment coding for amino acid 
residues 107~63 (CD-92) was amplified by PCR, ligated to the leader 
sequence of KC eDNA [17], and subcloned into pCAGGS to obtain 
pCAGGS92-CD. The recombinant DNAs were transfected into sub- 
confluent COS-7 by electroporation f 8 x 106/ml cells at 1500 V, 1000 
I-tF [15]. The antisense clone was used as a control for mock transfec- 
tion. After 72 h incubation, the supernatant was collected for Western 
blot and zymography. For expression of 92-CD in E. coli, the same 
PCR fragment was cloned into pETM1 [17]. To obtain a truncated 
92-CD without he zinc-binding site (t92-CD), a fragment correspond- 
ing to amino acid 107~,09 (t92-CD) was amplified by PCR and 
cloned into pETM1. The recombinant plasmids, pET92-CD and 
pETt92-CD, were transformed into BL21(DE3). After induction, the 
inclusion bodies were extracted with a buffer containing 6 M urea and 
loaded on a Ni-NTA affinity column (Qiagen, Chatsworth, CA). The 
purification procedure was carried out as described previously l18]. To 
refold the protein on column, refolding buffer containing 5 mM 
CaCle/20 mM Tris/0.2 M NaCI with urea gradient of 4 M 0.5 M 
was added at a rate of 0.5 ml/min. After refolding, the protein was 
eluted with 80 mM imidazole/5 mM CaCI~/20 mM Tris/0.2 M NaCI/ 
0.5 M urea and then dialyzed against phosphate-buffered saline (PBS). 
For zymography, the method escribed by Hibbs et al. [19] was used. 
The 92-CD was expressed in E.coli and used to immunize a rabbit 
as described previously l17]. Western blot was carried out as described 
previously [15]. Collagenase activity was studied using 10 ~tg of rat tail 
type I collagen (Boehringer Mannheim, Indianapolis, IN) incubated 
with different amounts of recombinant protein and enzyme inhibitors 
for 4 h at 37°C. The reactions were stopped by adding SDS sample 
buffer containing I~-ME, boiled and loaded for SDS-PAGE. The pro- 
tein bands were visualized with Coomassie Blue staining. 
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Fig. 1. Comparison of amino acid sequences of human, rat, and 
mouse 92-kDa type IV collagenase deduced from cDNA sequences. 
Accession number of the rat 92-kDa type IV collagenase, U36476. 
Numbering of the amino acids is shown beginning with the first re- 
sidue of the propeptide; residues of the signal peptide have negative 
numbers. Residues of identity are linked with bars. The conserved 
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Fig. 2. 92-kDa type IV collagenase (92) and 72-kDa type IV col- 
lagenase (72) expression in fetal (F), newborn (N), and adult (A) rat 
tissues assessed by RNase protection assay. 
3. Results and discussion 
3.1. Chining of  rat 92-kDa type IV  collagenase 
Four positive clones, each being 1.9 kb in size, were iso- 
lated. Sequence analysis revealed that these four clones were 
identical and all were partial eDNA clones containing only 
the 1752 bp coding sequence (nt 375-2127). Further screening 
of the same eDNA library did not yield any clone with addi- 
tional 5' sequences, and polymerase chain reaction (PCR) 
using the 5' end primer confirmed that this library does not 
contain full-length eDNA clones for rat 92-kDa type IV col- 
lagenase. Similar difficulties have been encountered by other 
groups in cloning the cDNA of three other MMPs - -  human 
and rat 72-kDa type IV collagenase (gelatinase A) [7,9,20] and 
mouse 92-kDa type IV collagenase [8] - -  a problem likely to 
have arisen from site-specific premature termination of first- 
strand synthesis during eDNA library construction. To con- 
struct the full-length cDNA, a primer containing the con- 
served 5'-end sequence between human and mouse 92-kDa 
type IV collagenase was used in RT-PCR of fetal rat kidney 
total RNA. A 375 bp RT-PCR band was obtained and pieced 
together with the 1.9 kb partial eDNA. This full-length eDNA 
was completely sequenced, and Fig. 1 shows the amino acid 
sequences deduced from the eDNA sequence (Accession 
#U36476). Comparison of amino acid sequences of the rat 
92-kDa type IV eollagenase to that of the human and mouse 
shows a 74% and 80% homology, respectively. Interestingly, 
the rat enzyme lacks the two extra stretches of amino acids 
present in the type V collagen and the hemopexin domains of 
the murine enzyme (Fig. 1). In addition to the coding region, 
the cDNA also contains a 217 bp 3 'UTR including the trans- 
lation stop codon TGA and the polyadenylation signal (data 
not shown). 
3.2. Tissue-specific expression of  mRNA for 72-kDa and 92- 
kDa type IV  eollagenase 
RNase protection assay was used to determine and compare 
the mRNA expression of the 72-kDa and 92-kDa type IV 
collagenases in various tissues (Fig. 2). As can be seen, ex- 
pression of  both enzymes is tissue specific and differentially 
regulated during development. The 92-kDa type IV collage- 
nase expression was more restricted, compared with that of 
the 72-kDa type IV collagenase. In the fetal and newborn 
kidney as well as in fetal spleen, the 92-kDa type IV collage- 
nase is actively expressed, suggesting its role in the develop- 
ment of rat kidney and spleen. 
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3.3. Expression and characterization of  rat 92-kDa type IV  
collagenase and its catalytic domain (92-CD) 
Full-length uman 92-kDa type IV collagenase as well as a 
number of other full-length MMPs have been expressed in 
and purified from E. coli [21-23]. While all these full-length 
MMPs are active after organomercurial or proteolytic activa- 
tion, they quickly degenerate due to autolysis of the C-term- 
inal domains. To circumvent his problem, the cDNA was 
modified and the recombinant protein expressed to obtain 
an abundant source of active and stable enzyme. Matrilysin 
(PUMP; MMP-7) naturally lacks the C-terminal hemopexin- 
like domain and is an active enzyme [24]. Stromelysin and 72- 
kDa type IV collagenase are active with this domain removed 
[25-27]. On the other hand, fibroblast and neutrophil collage- 
nases lacking the C-terminal domain lose the degradative ac- 
tivity against collagens [28,29]. To investigate the effect of C- 
terminal domain deletion on the 92-kDa type IV gelatinase, 
the rat cDNA was subcloned into various vectors and ex- 
pressed in different hosts. To minimize other complicating 
factors like glycosylation and protein folding, the full-length 
and truncated rat 92-kDa type IV collagenase were expressed 
in mammalian cells. This was done by subcloning the full- 
length and truncated fragments of rat 92-kDa type IV collage- 
nase cDNA into mammalian expression vector pCAGGS and 
transfecting different constructs into COS-7 cells. Both the 
full-length rat 92-kDa type IV collagenase and its catalytic 
domain (92-CD) expressed in COS-7 were in agreement with 
the calculated molecular mass as judged by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), gela- 
tinolytic zymogram, and Western blot (Fig. 3). In the super- 
natant of full-length 92-kDa type IV collagenase transfectant, 
an extra band appeared, indicating that it is secreted and 
processed (Fig. 3). 
Two recombinant forms, 92-CD (coding for amino acid 
residues 107-463) and truncated 92-CD (t92-CD, 107-409), 
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Fig. 3. Expression of rat 92-kDa type IV collagenase and/or its deri- 
vatives in various host cells. (A) SDS-PAGE analysis of the expres- 
sion of 92-CD in E. coli. Lane 1, non-induced; lane 2, induced with 
IPTG for 2 h; lane 3, affinity-purified 92-CD; lane 4, rainbow mar- 
ker (Amersham, Arlington Heights, IL). (B) Gelatin zymogram ana- 
lyses of the recombinant proteins. Lane 1, 92-kDa type IV collagen 
antisense in COS-7; lane 2, full-length sense 92-kDa type IV col- 
lagenase in COS-7; lane 3, 92-CD in COS-7; lane 4, 92-CD in E. 
coli; lane 5, t92-CD. The arrow denotes processed 92-kDa type IV 
collagenase. (C) Western blot analysis of full-length 92-kDa type IV 
collagenase xpressed in COS-7 cells. Western immunoblotting was 
carried out using a rabbit polyclonal antibody raised against he 92- 
CD expressed in E. coli. Lane 1, antisense, and lane 2, sense, from 
the transfectant supernatant of COS-7 cells. 
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Fig. 4. SDS-PAGE analysis of collagenase activity of 92-CD and 
t92-CD is shown. Lane l is the rainbow marker. 10 ~tg of rat type I 
collagen was incubated with t92-CD or 92-CD in the presence of 
the inhibitors; t92-CD had no effect on collagen digestion (lane 2). 
Dose-dependent digestion of collagen by recombinant 92-CD at 10 
ng, 20 rig, 100 ng, and 200 ng is shown (lane 3 to lane 6). 1 mM of 
EDTA and 5 mM of phenanthroline w re shown to inhibit the col- 
lagen digestion of 200 ng 92-CD (lanes 7 and 8). Collagen alone 
without enzyme is shown in lane 9. 
of rat 92-kDa type IV collagenase were expressed in E. coil. 
The t92-CD was without the zinc-binding domain and served 
as a negative control. The purified 92-CD and t92-CD were 
expressed as a single band at 38-kDa and 29-kDa, respec- 
tively, in agreement with the calculated molecular weight 
(Fig. 4). The recombinant 92-CD and t92-CD were present 
in inclusion bodies. The 92-CD was extracted from the inclu- 
sion bodies and was functionally renatured with a high yield 
(40 mg/liter) following the method previously described [17]. 
The refolded 92-CD was fully active, sensitive to inhibitors, 
and very stable (Fig. 4). 
Type IV collagenases have been shown to be important 
proteinases in tissue remodeling in many physiological and 
pathological processes. The high level and functional expres- 
sion of the catalytic domain of 92-kDa type IV in E. coli 
provides a recombinant protein suitable for structure determi- 
nation by nuclear magnetic resonance spectroscopy and X-ray 
crystallography, as well as for mechanistic studies of catalysis 
and inhibition. Availability of the rat probe and antibody will 
be useful in studying pathological and physiological functions 
of this enzyme in rat model systems for human diseases. 
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